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Regulatory T cellType 1 diabetes mellitus (T1D) is caused by the destruction of insulin-producing β cells in pancreatic islets by
autoimmune T cells. Islet transplantation has been established as an effective therapeutic strategy for T1D. How-
ever, the survival of islet grafts can be disrupted by recurrent autoimmunity. Dimethyl sulfoxide (DMSO) is a sol-
vent for organic and inorganic substances and an organ-conserving agent used in solid organ transplantations.
DMSO also exerts anti-inﬂammatory, reactive oxygen species scavenger and immunomodulatory effects and
therefore exhibits therapeutic potential for the treatment of several human inﬂammatory diseases. In this
study, we investigated the therapeutic potential of DMSO in the inhibition of autoimmunity. We treated an ani-
mal model of islet transplantation (NOD mice) with DMSO. The survival of the syngeneic islet grafts was signif-
icantly prolonged. The population numbers of CD8, DC and Th1 cells were decreased, and regulatory T (Treg) cell
numbers were increased in recipients. The expression levels of IFN-γ and proliferation of T cells were also
reduced following DMSO treatment. Furthermore, the differentiation of Treg cells fromnaive CD4 T cells was sig-
niﬁcantly increased in the in vitro study. Our results demonstrate for the ﬁrst time that in vivo DMSO treatment
suppresses spontaneous diabetes and autoimmune recurrence in NOD mice by inhibiting the Th1 immune
response and inducing the differentiation of Treg cells.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Autoimmune diabetes, formally referred to as type 1 diabetes, re-
sults from the destruction of insulin-producing β cells in the islet of
the pancreas and has been identiﬁed as a T cell-mediated autoimmune
disease (Kawasaki et al., 2004). The development of T1D is usually diag-
nosed in young patients; thus, this disease is also termed juvenile-onset
diabetes or childhood-onset diabetes. T1D only exhibits 30–50% concor-
dance in monozygotic twins (Barnett et al., 1981), thereby suggesting
that both genetic predisposition and environmental factors contributeice, non-obese diabetic mice;
ndritic cells; IFN, interferon; IL,
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. This is an open access article underto the pathogenesis of diabetes (Kaufman et al., 1992; Abdeen et al.,
2007; Nejentsev et al., 2007). The NOD mouse model is frequently
used for T1D studies. This mouse model spontaneously develops T
cell-dependent β cell destruction resembling human T1D and serves
as an animal model for this autoimmune disease (Aoki et al., 2005).
The classical therapeutic strategy for patientswith T1D is the admin-
istration of insulin injections tomaintain normal levels of blood glucose.
However, this approach is unable to provide real-time blood glucose
modulation and is ineffective inmaintaining stable blood glucose levels,
which frequently leads to clinical complications, such as retinopathy,
nephropathy, neuropathy and macrovascular disease (O'Brien and
Corrall, 1988). Maintaining stable glucose levels is important to prevent
the development of secondary complications in T1D.
Islet transplantation has been reported as an effective strategy to ac-
complish insulin independence, normoglycemia and long-term hemo-
stasis of blood glucose in T1D patients (Gaglia et al., 2005). Moreover,
islet transplantation is relatively simple to administer, as it does notthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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out-patient basis under local anesthesia and can be repeated several
times without major discomfort to the patient (Bottino et al., 2002).
Islet transplantation achieves nearly perfect blood glucose monitoring
and modulation in T1D patients (Gaglia et al., 2005). However, islet
grafts have been shown to be destroyed due to allogeneic graft rejection
and autoimmune recurrence (Balamurugan et al., 2006). Autoreactive
T cells harbor thememory of β cells and are responsible for this autoim-
mune recurrence. Islet grafts in NOD mice frequently undergo early
graft failure because of the immediate destruction of the graft before im-
munological graft rejection (Gysemans et al., 2000; Okitsu et al., 2001).
Young et al. (2004) have also demonstrated that transplanted islet
grafts in NODmice are susceptible to recurrent autoimmunity. Previous
studies have reported that human islets from genetically identical twins
(Sibley et al., 1985) or cadaver donors (Tyden et al., 1996) were
destroyed by recurrent autoimmunity. Therefore, the establishment of
a strategy to suppress autoimmune recurrence is critical for islet trans-
plantation in patients with T1D.
Dimethyl sulfoxide (DMSO) is a colorless, hygroscopic liquid chem-
ical that is a powerful solvent for organic or inorganic substances. It is
used for a variety of laboratory and clinical purposes. DMSO is frequent-
ly used as a solvent in biological studies and a vehicle for drug therapy.
Moreover, DMSO has been applied for therapeutic purposes in several
clinical diseases. It has been approved by the United States Food and
Drug Administration for the treatment of interstitial cystitis by
intravesical instillation (Kato et al., 2000; Santos et al., 2003). It also
been used to treat localized amyloidosis and improves renal function
and proteinuria in renal amyloidosis patients caused by Crohn's disease
(Iwakiri et al., 1999; Kato et al., 2000; Amemori et al., 2006). Further-
more, DMSO is a hydrogen-bond disrupter, hydroxyl radical scavenger
and cryoprotectant (Amemori et al., 2006). Due to anti-inﬂammatory
properties of DMSO, it has been justiﬁed for the treatment of inﬂamma-
tory diseases (e.g., scleroderma, osteoarthritis, and rheumatoid arthritis)
(Kato et al., 2000; Santos et al., 2003), gastrointestinal diseases (Salim,
1991a,b, 1992), some manifestations of amyloidosis (Morassi et al.,
1989; Iwasaki et al., 1994; McCammon et al., 1998; Ozkaya-Bayazit
et al., 1998), brain edema (Ikeda and Long, 1990) and chronic prostatitis
(Shirley et al., 1978).
The immunomodulatory function of DMSO has recently been de-
scribed. Kloverpris et al. (2010) have reported that proliferative and se-
cretion of inﬂammatory cytokines in human CD4 and CD8 T cells were
reduced following treatment in 2–3% DMSO solution for 7 days. Lin
et al. (1995) have demonstrated that a 4-day treatment with DMSO
(N2%) induces apoptosis in Burkitt Lymphoma cells. Given these
immunomodulation and anti-inﬂammatory effects of DMSO,we further
investigated whether DMSO treatment prevents the onset of spontane-
ous diabetes and prolongs the survival of islet grafts in a syngeneic islet
transplantation model. Our results demonstrate that DMSO treatment
signiﬁcantly prevented the onset of diabetes and prolonged islet graft
survival in NOD mice. To elucidate the mechanisms of this protective
effect, we investigated the inﬂuence of DMSO on immune cells with
regard to cytokine proﬁles and proliferation of T cells. DMSO treatment
reduced the proportion of cytotoxic T cells and DCs and increased the
proportion of Treg cells in the spleens of NOD recipients. We further
demonstrated that DMSO increases the differentiation of Treg cells
from the naive CD4 T cells of NOD mice. Overall, DMSO treatment re-
duced diabetic incidence in NOD mice and prolonged the survival of
syngeneic islet grafts. This protective effect is, at least partly, associated
with increased differentiation of Treg cells in themodulation of immune
cell effector functions.
Materials and methods
Animals. Inbred NOD/Sytwu mice (Kd, Db, Ld, I-Ag7) and NOD/scid mice
were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and
subsequently bred at the animal center of the National DefenseMedicalCenter in Taipei, Taiwan, under speciﬁc pathogen-free conditions. The
spontaneous incidence of diabetes in the colonywas 80–90% in females
and 20–30% in males by 30 weeks of age.
Islet transplantation. Newly diagnosed NOD female mice, with blood
glucose levels between 300 and 500 mg/dL for two consecutive days,
were used as recipients for islet transplantation as previous described
(Lin et al., 2009). The syngeneic islets were isolated from 5- to 8-
week-old non-diabetic male NOD mice. The onset of autoimmune dia-
betes in male NOD mice is later than female; therefore, we can isolate
more intact islets formmale NODmice by this age. Islets measuring be-
tween 75 and 150 μm in diameters were selected by hand. Islets (700)
were transplanted into the kidney subcapsular space of the recipients.
Blood glucose levels lower than 200 mg/dL on the ﬁrst and second day
after islet transplantation were considered to represent a successful
transplantation.
Blood glucose monitoring. Blood glucose was monitored daily with a
blood glucose test strip (MediSense Optium Xceed, Abbott Diabetes
Care Inc., Alameda, CA, USA). Graft rejection was deﬁned as blood glu-
cose levels higher than 300 mg/dL for 2 consecutive days.
Histological analysis. Kidneys were harvested from NOD recipients and
then embedded in OCT. Sections (4 μm in thickness) were cut and
stained with hematoxylin and eosin (H&E) staining and then analyzed
via light microscopy.
Insulin secretion test. Islets were isolated from untreated control mice,
PBS-treatedmice, andDMSO-treatedmice. Fifteen isletswere incubated
in F12K medium (Gibco, Auckland, NZ) containing 16.7 mM or 2.8 mM
glucose for 1 h in Transwell plates. At the end of incubation period, islets
were removed and the secreted insulin in the medium was measured
with a mouse insulin ELISA kit (Mercodia, Uppsala, Sweden). The stim-
ulation index was calculated with the ratio of insulin secreted at 16.7
and 2.8 mM glucose incubated for 1 h.
T cell proliferation. Splenocytes isolated from female NOD mice were
treated with Tris-buffered ammonium chloride to eliminate erythro-
cytes. After washing, cells were resuspended at a concentration of 5
× 106 cells/mL in RPMI1640 medium supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin. The cells were
stimulated with plate-coated anti-CD3 antibody (Clone 145-2C11;
BD Biosciences Pharmingen, San Jose, CA, USA), or concanavalin A
(Con A; Sigma-Aldrich, Saint Louis, MO, USA). When stimulated
with islet antigen, the cells were resuspended in serum-free RPMI-
1640 supplemented with 100 U/mL penicillin G, 0.1 mg/mL strepto-
mycin, 0.1 mM MEM non-essential amino acids (NEA, GIBCO
Invitrogen, Carlsbad, CA, USA) and 50 μM 2-mercaptothanol (2-ME;
Sigma-Aldrich, Saint Louis, MO, USA). After 54 h, the cultured cells were
pulsed with 1 μCi of 3H-methyl thymidine (PerkinElmer, Waltham, MA,
USA). The plates were then harvested onto a UniFilter-96, GF/C
(PerkinElmer) at 72 h. The incorporated 3H-methyl thymidine was mea-
sured at 72 h with a TopCount liquid scintillation counter (Packard
Instrument Co.,Meriden, CT, USA). The level of [3H]-thymidine incorpora-
tion for each group was normalized to that of the unstimulated control,
thereby producing a ratio referred to here as the stimulation index (S.I.).
Flow cytometry. Lymphocytes were harvested from spleen stained with
allophycocyanin-conjugated anti-mouse CD4 (clone GK1.5), phycoery-
thrin (PE)-conjugated anti-mouse CD8α (clone 53-6.7), ﬂuorescein iso-
thiocyanate (FITC)-conjugated anti-mouse CD19 (clone 1D3), and PE-
conjugated anti-mouse CD25 (clone PC61) (BD Pharmingen) for
30 min at 4 °C. For Foxp3 staining, the cells stained with surface mole-
cules were ﬁxed and permeabilized overnight with Fixation/Perme-
abilization working solution (eBioscience Inc., San Diego, CA, USA).
Fig. 1. DMSO treatment delays spontaneous diabetic frequency and prolongs islet graft survival in the syngeneic islet transplantation of NOD mice. (A) Spontaneous diabetes in DMSO-
treated NOD mice or PBS-treated NOD mice was monitored via weekly measurement of glycosuria. Diabetic frequency was signiﬁcantly reduced in the DMSO-treated group (p b 0.05).
(B) Syngeneic islet grafts in PBS-treated mice were destroyed by day 20 post-transplantation (mean survival 8.8 ± 5.05 days, n= 10). The survival time of islet grafts in DMSO-treated
mice was prolonged for up to 26 days (mean survival 22.29 ± 8.35 days, n= 7, p b 0.001 compared with PBS-treated groups). Data are presented as the mean ± SD. (C) The number of
inﬁltrating lymphocytes in islet grafts was lower in the DMSO-treated group at day 10 after transplantation.
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conjugated anti-Foxp3 (clone FJK-16S) (eBioscience Inc.). For intracel-
lular cytokine staining, the cells were stimulated for 4–6 h with
20 ng/mL phorbol 12-myristate 13-acetate and 1 μM ionomycin in the
presence of 4 μM monensin. The eBioscience ﬁxation and perme-
abilization kit was used for intracellular cytokine staining. Stimulated
cells were stained with antibody to surface CD4 (RM4-5, APC-
conjugated, 0.25 μL/test) on ice for 25–30minutes (in the dark),washed
with 1 mL of FACS buffer (PBS containing 0.5% FBS), and ﬁxed with
0.1 mL of IC Fixation Buffer (eBioscience Inc.) for 20minutes at ambient
temperature (in the dark). After washingwith 1mL of permeabilization
buffer (eBioscience Inc.), the cells were resuspended in 80 μL of perme-
abilization buffer and incubated at ambient temperature for 10minutes.
The cells were then stained with FITC-conjugated anti-IL-10 antibody
(clone JES5-16E3) (eBioscience Inc.) at ambient temperature for 20 mi-
nutes. Flow cytometric analysis was performed with a FACS Calibur (BD
Pharmingen) and CellQuest software (Becton Dickinson, San Jose, CA,
USA).Quantitative real-time polymerase chain reaction (PCR). Total RNA
was prepared from splenocytes using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) in accordance with the manufacturer's protocols.
Brieﬂy, 2 × 106 splenocytes were suspended in 1 mL of TRIzol reagent
and incubated at ambient temperature for 3 minutes. After adding
0.2 mL of chloroform, the tube was agitated by hand for 15 seconds
and then incubated at ambient temperature for 2–3 minutes. The sus-
pensionwas centrifuged at 12,000g for 15minutes at 4 °C, and the aque-
ous phase was then transferred to a new Eppendorf tube. After adding
0.5 mL of isopropyl alcohol and incubating the suspension at ambient
temperature for 10minutes, the RNA pellet was precipitated via centri-
fugation at 12,000g for 10 minutes at 4 °C. The RNA pellet was subse-
quently washed with 1 mL of 75% ethanol and centrifuged again at
7500g for 5minutes at 4 °C. The RNApelletwasdried and then dissolvedin an appropriate volume of 0.1% DEPC-treated sterile water. Next, 5 μg
of total RNA was reverse-transcribed with oligo dT and SuperScript III
Reverse Transcriptase (Invitrogen) using oligo (dT)18 primers. Real-
time PCR was performed using an iCycler (Bio-Rad, Hercules, CA, USA)
with iQ SYBR Green PCR SuperMix (Bio-Rad). The threshold cycle (Ct)
value was deﬁned as the cycle number at which the ﬂuorescence
crossed a ﬁxed threshold above the baseline. For relative quantiﬁcation,
fold changes were measured using the ΔΔCt method. For each sample,
the Ct value of cytokine mRNA was measured and compared with the
HPRT endogenous control as ΔCt (ΔCt = Ctcytokine − CtHPRT). The
cytokine mRNA fold change in experimental samples relative to
control samples was determined using 2−ΔΔCt, in which ΔΔCt =
ΔCtexperiment− ΔCtcontrol.In vitro Treg cell differentiation. Naive CD4+ T cells were harvested and
sorted from the splenocytes of NOD mice and then cultured for 1 day
with human IL-2 cytokine (5ng/mL). These naive CD4+ T cellswere cul-
turedwith PBS, 0.5%DMSO, or 1%DMSO for 0, 6 or 24h. CD4CD25 foxp3
cells were then measured from these naive CD4+ T cells via ﬂow
cytometry.Western blots. Cells were lysed with 10 mM Tris, 1 mM EDTA, 10 mM
KCl and 0.3% Triton, pH 7.9. Proteins were separated on 12% SDS–poly-
acrylamide gels and electrophoretically transferred to immobilon-P
transfer membranes (Millipore, USA). The membranes were blocked
with 5% skimmedmilk and then incubated with the primary antibodies
at 4 °C overnight in TBS-T (10 mM Tris HCl pH 8.0, 150 mM NaCl, and
0.1% Tween-20) followed by a 2 h incubationwith peroxidase conjugat-
ed secondary antibodies. The protein signals were visualized using an
ECL kit (Amersham, Little Chalfont, UK). The following primary antibod-
ies were used: STAT5 (GeneTex, Hsinchu City, Taiwan), phosphorylated
STAT5 (GeneTex) and β actin (GeneTex).
Fig. 2. DMSO treatment does not affect body weight and insulin secretion in NOD recipi-
ents. (A) There were no signiﬁcant differences in the body weight of PBS-treated and
DMSO-treated mice (p N 0.05, n = 3). (B) Islets isolated from PBS- and DMSO-treated
mice were stimulated with 2.8 mM or 16.7 mM glucose for 1 h. The stimulation index
was calculated with the ratio of insulin secreted at 16.7 and 2.8 mM glucose (n= 5). No
signiﬁcant differences between PBS-treated and DMSO-treated groups were observed
(p N 0.05). The data are expressed as the mean ± SEM (n= 6).
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The signiﬁcance of islet graft survival time between the PBS-treated
and DMSO-treated groups was determined via Kaplan-Meier survival
analysis. The signiﬁcance of diabetic frequency between the PBS-
treated and DMSO-treated NOD mice was also determined via Kaplan-
Meier survival analysis. For the remaining experiments, P values were
calculated using the two-tailed Student's t test or ANOVA test. Differ-
ences are considered signiﬁcant at P b 0.05.Results
DMSO treatment delayed the onset of autoimmune diabetes and prolonged
the survival of syngeneic islet grafts after islet transplantation
To evaluate the protective effect of DMSO in autoimmune diabetes,
the 4-week-old female NOD mice were treated with DMSO (0.22 g/kg/
day) at 2-day intervals for 4 weeks (16 doses in all for long term thera-
py). The incidence of spontaneous autoimmune diabetes was signiﬁ-
cantly lower and the onset of disease was delayed in the DMSO-
treated group (Fig. 1A). To investigate whether DMSO treatment pro-
tects β cells from autoimmune recurrence, we performed syngeneic
islet transplantation. We isolated islets from male NOD mice (age: b8weeks) and implanted these islets into the left kidney capsule of
newly diabetic female NOD recipients. NOD recipients were treated
with DMSO (0.22 g/kg/day) daily for a total of 9 days. The treatment
was initiated at 1 day prior to islet transplantation (day−1). The entire
treatment process was carried out until day 7 post islet transplantation
(from day−1 to day 7). In most PBS control recipients, hyperglycemia
recurred within 11 days after transplantation, and the mean graft sur-
vival time was 8.8 days. In contrast, the islet grafts in most DMSO treat-
ed recipients survive up to 20 days, and the mean graft survival time
was 22.29 days (Fig. 1B). The biopsy of islet grafts at day 10 after trans-
plantation exhibited low leukocyte inﬁltration, and more intact islets
were observed in the grafted area of the DMSO-treated NOD recipients
compared with PBS controls (Fig. 1C). These data indicate that DMSO
treatment not only prevents the onset of spontaneous autoimmune di-
abetes, but it also prolongs the survival of islet grafts after syngeneic
islet transplantation.DMSO treatment did not affect body weight and insulin secretion in
NOD mice
To evaluate the effect of DMSO treatment on the general physiology
of diabetic NODmice, we treated newly diabetic NODmice with DMSO
at 0.22 g/kg/day for 9 days andmonitored bodyweight daily. The mean
body weight of female diabetic NOD mice showed no apparent differ-
ence between DMSO-treated or PBS-treated controls (Fig. 2A). To inves-
tigate whether the effect of DMSO on the prolonged survival of islet
grafts was caused by increased insulin production, we examined insulin
secretion in islets from PBS- or DMSO-treated NOD mice. The levels of
insulin secretion from islets incubated in medium with high or low
concentrations of glucose displayed no signiﬁcant difference between
control and DMSO-treated groups. There was also no signiﬁcant differ-
ence in the stimulation index between these 2 groups (Fig. 2B). These
results indicate that DMSO treatment did not inﬂuence body weight in
NOD mice or the production of insulin in islets.DMSO treatment reduced Th1 immune response and increased the
population of regulatory T cells
To evaluate the modulatory effect of DMSO treatment on T cells, we
analyzed the proportion of different T cell subsets in the spleens at day
8 after islet transplantation in NOD recipients treated with DMSO
(at 0.22 g/kg/day for 9 days). No signiﬁcant difference was found in
the percentage of CD4 T cells in the spleens of experimental mice
(Fig. 3A). In contrast, the percentage of CD8 T cells was signiﬁcantly de-
creased in the DMSO-treated group compared with the PBS-treated
group (Fig. 3B, P b 0.05). Moreover, the population of CD11c dendritic
cells (DCs) was also signiﬁcantly decreased in the DMSO-treated
group (Fig. 3C, P b 0.05). We further evaluated the subpopulations of
CD4 T lymphocytes as well as the proportions of IFN-γ-producing CD4
cells (Th1 cells), IL-4-producing CD4 cells (Th2 cells) and regulatory T
cells (Treg cells). A signiﬁcant reductionwas observed in the percentage
of the Th1 subpopulation (Fig. 3D, P b 0.05), while no signiﬁcant differ-
ence in IL-4-producing CD4 cells (Th2 cells) was found (Fig. 3E). How-
ever, the CD4 CD25 Foxp3 cell (Treg cell) population was signiﬁcantly
increased in the DMSO-treated group (P b 0.05) (Fig. 3F, P b 0.05). We
also analyzed the expression of IFN-γ and IL-4 cytokines in the
splenocytes (Figs. 4A and B) of PBS or DMSO-treated NODmouse recip-
ients via real-time RT-PCR. The levels of IFN-γ were signiﬁcantly de-
creased with DMSO treatment. However, the levels of IL-4 cytokine
displayed no difference between the DMSO-treated and PBS-treated
groups. These results suggest that the extended survival of syngeneic
islet grafts in recipients may be attributed to the DMSO-mediated de-
creases in CD8, DC and Th1 cells, which is likely acting via modulation
of Treg cells in the experimental mice.
Fig. 3. DMSO treatment reduces the population of CD8 cells, Th1 cells and DCs, and increases Treg cells in the spleen of NOD mice. The (A) CD4 T lymphocytes, (B) CD8 T lymphocytes,
(C) DCs, (D) Th1 cells, (E) Th2 cells and (F) Treg cells were isolated from the spleens of DMSO-treated and PBS-treated NOD recipients at day 8 post-transplantation and then analyzed
via ﬂow cytometry. *p b 0.05. (n= 4).
Fig. 4. DMSO treatment reduces IFN-γ cytokine expression in the splenocytes of NOD
mice. The (A) IFN-γ and (B) IL-4 cytokine expression levels in splenocytes isolated from
DMSO-treated or PBS-treated regular NOD female mice were analyzed via real time
RT-PCR. *p b 0.05. The data are expressed as the mean ± SEM (n= 3).
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To testwhether the proliferative capacity of splenocytes in grafted re-
cipientswas reduced by DMSO treatment, we evaluated the proliferation
of splenocytes via 3H-thymidine incorporation assay. Islet-transplanted
NOD mice were treated with DMSO (at 0.22 g/kg/day for 9 days) or
PBS for 9 days; splenocytes were then harvested and stimulated with
α-CD3 (0.25, 0.5, 1, and 2 μg/mL) and Con A (0.25, 0.5, 1, and 2 μg/mL),
respectively. The proliferation of splenocytes harvested from the
DMSO-treated mice was signiﬁcantly reduced compared with theFig. 5. DMSO treatment inhibits the proliferation of T lymphocytes in islet-transplanted
NOD mice. The islet-transplanted NOD mice were treated with DMSO or PBS for 9 days.
Splenocytes were harvested and stimulated with α-CD3 (0.25, 0.5, 1, and 2 μg/mL) and
Con A (0.25, 0.5, 1, and 2 μg/mL). The number of splenocytes harvested from DMSO-treated
mice was signiﬁcantly reduced compared with the PBS-treated group (*p b 0.05). The data
are expressed as the mean ± SEM (n= 3).
Fig. 7. DMSO treatment increased STAT5 and phosphorylated STAT5 levels in CD4 T lym-
phocytes of NODmice. The CD4 naive T lymphocytes were cultured with various concen-
trations of DMSO solutions (0%, 0.5% and 1%) at different incubation times (0 h, 6 h and
12 h). After DMSO solution treatment, the levels of STAT5 and phosphorylated STAT5
(P-STAT5) were assessed via western blot. The result is representative of three indepen-
dent experiments.
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(Fig. 5). These results suggest that the proliferative ability of T cells in
the splenocytes of NOD recipients was inhibited by DMSO treatment.
DMSO treatment induced Treg differentiation from naive CD4 T cells
To investigate whether the protective effect of DMSO treatment acts
via the induction of Treg cell differentiation, we examined the ability of
Treg cell differentiation from naive CD4 T cells in NOD recipients with
DMSO treatment. These naive CD4 T cells were cultured in different
concentrations of DMSO-containing medium (0%, 0.5% and 1%) at vari-
ous time periods (0, 6, and 12 h). The percentages and absolute num-
bers of Treg cells differentiated from these naive CD4 T cells were
assessed via ﬂow cytometry. The percentages and absolute numbers of
Treg cells were signiﬁcantly increased following DMSO treatment in a
dose-dependent manner (Figs. 6A and B). We also examined the inﬂu-
ence of DMSO treatment in the activation of the STAT5 signaling path-
way, which is a critical factor in Treg cell differentiation (Burchill et al.,
2007). The expression levels of STAT5 and the phosphorylation of
STAT5 (STAT5-P) were increased following DMSO treatment in a time
dependent manner (Fig. 7). These results suggest that the protectiveFig. 6.DMSO treatment increased the differential population and cell number of Treg lym-
phocytes in the naive CD4 T lymphocytes of NOD mice. Naive CD4 T lymphocytes were
culturedwith differential concentrations of DMSO solutions (0%, 0.5% and 1%) for different
incubation times (0 h, 6 h and 24 h). After DMSO solution treatment, the percentage and
number of Treg lymphocytes were analyzed via ﬂow cytometry. The (A) percentages and
(B) numbers of Treg cells differentiated from naive CD4 T lymphocytes following DMSO
treatment at different concentrations and incubation times were increased (⁎p b 0.05,
⁎⁎p b 0.01, , ⁎⁎⁎p b 0.001). The data are expressed as the mean ± SEM (n= 6).effect observed with DMSO treatment in syngeneic islet transplanta-
tions may be attributed to the DMSO-mediated modulation of Treg
cell differentiation in recipients.
Discussion
T1D is an autoimmune disease caused by the destruction of islet β
cells by autoreactive immune cells (Kawasaki et al., 2004). However,
most T1D patients are diagnosed after diabetes onset. Islet transplanta-
tion has been attempted as an effective therapy strategy for T1D
(Bottino et al., 2002) due to the lower cost and higher safety compared
with pancreas transplantation (Robertson, 2004; Gaglia et al., 2005).
However, recurrent autoimmunity plays a crucial role in islet graft
destruction and impairs the survival of islet grafts in human islet trans-
plantation. Moreover, destruction of grafts by autoimmune recurrence
often takes place earlier than allogeneic graft rejection (Balamurugan
et al., 2006; Huang et al., 2013). Therefore, it is important to overcome
recurrent autoimmunity in islet transplantation.
DMSO is a frequently used solvent for organic or inorganic substances.
It also exhibits therapeutic beneﬁts, including anti-inﬂammation and
anti-ROS effects, in the treatment of several human diseases, such as in-
terstitial cystitis and rheumatoid arthritis (Kato et al., 2000; Santos et al.,
2003). Recently, the immune-modulatory effect of DMSO has been re-
ported by Henrik Kloverpris et al. (2010). Human T cell line responses
are completely abrogated by DMSO treatment at concentrations between
2.5% and 5% for 6 h (Kloverpris et al., 2010). In this study, we investigated
the protective effects of DMSO treatment on the prevention of spontane-
ous diabetes and the inhibition of autoimmune recurrence in islet graft
rejection with a safe dosage. This is the ﬁrst report showing that DMSO
treatment effectively suppresses the onset of autoimmune diabetes and
prolongs the survival of islet grafts. Our results also demonstrate that
DMSO treatment reduces the population of dendritic cells and Th1 cells
among the splenocytes of NOD mice. Furthermore, we also found that
this treatment increased the percentages of Treg cells among splenocytes,
thereby suggesting thatDMSOexerts an inductive effect in the generation
of Treg cells. This increase in Treg cells may explain the suppressive effect
of DMSOon the population of Th1 cells aswell as the production of IFN-γ.
We further examined whether DMSO treatment induces the genera-
tion of Treg cells. We found that DMSO treatment induced the differenti-
ation of Treg cells from naive CD4 T lymphocytes, thereby demonstrating
a novel effect of DMSO in the production of Treg cells. Therefore, we fur-
ther investigated the underlying mechanism in the increase of Treg cells
inducedbyDMSO. Aprevious studyhas reported that the STAT5 signaling
pathway is required for the development of Treg cells (Burchill et al.,
2007). A recent study has also demonstrated that STAT5 polarization pro-
motes Treg cell generation (Betts et al., 2014). These results highlight the
213G.-J. Lin et al. / Toxicology and Applied Pharmacology 282 (2015) 207–214importance of the STAT5 signaling pathway in the production of Treg
cells. Therefore, we investigated whether DMSO-induced Treg differenti-
ation acts via enhancement of the activation of the STAT5 signaling path-
way. We found that the levels of STAT5 protein and phosphorylated
STAT5 were increased following DMSO treatment, thereby suggesting
that DMSO may promote differentiation of Treg cells via enhanced the
activation of the STAT5 signaling pathway.
Amajor concern inmedicinal therapy for themodulation of immune
responses is the safety of drug administration. DMSO has been demon-
strated to elicit minor side effects in the clinical setting (Jacob and de la
Torre, 2009). The best known adverse reaction is intravascular hemoly-
sis after intravenous infusion of DMSO solution with concentrations
equal to or greater than 40% (Waller et al., 1983). This could be due to
the osmotic pressure in erythrocytes caused by DMSO (Wolf and
Simon, 1983), which can be prevented by using DMSO solution at less
than 30% (Karaca et al., 2002). Our data indicate that DMSO treatment
at the dosage of 0.22 g/kg/day in NOD mice was safe and yielded no
obvious diarrhea or weight loss. Furthermore, this treatment did not in-
terfere themetabolismof blood glucose and the insulin-secreting ability
of pancreatic cells in treated NODmice. Compared with DMSO, the side
effects of Tacrolimus (FK506), which is a calcineurin blocker for T cells
frequently used in the inhibition of allograft rejection, include the in-
duction of hyperglycemia or diabetes in recipients after human islet
transplantation (Nanji and Shapiro, 2004). This effect may alter the
insulin-secreting function of β cells in the islet by suppressing the
mRNA expression of insulin gene 1 and 2 (Hernandez-Fisac et al.,
2007). Furthermore, FK506 also affects glucose-induced insulin secre-
tion by interacting with the exocytotic machinery of the β cell. It has
been shown that dephosphorylation of kinesin heavy chain by the
Ca2+-dependent protein phosphatase 2B/calcineurinmight be required
for normal stimulation of the second (microtubule-dependent) phase of
glucose-induced insulin secretion (Heit et al., 2006). Thus, DMSO may
be an alternative therapeutic option for islet transplantation in the ther-
apy of T1D.
In conclusion, our study demonstrated for the ﬁrst time that DMSO
exerts therapeutic effects in the inhibition of autoimmune recurrence
in islet transplantation for T1D treatment. DMSO acts through the im-
mune modulatory effect by suppressing the Th1 immune response
and inducing Treg cell differentiation by enhancing the activation of
the STAT5 signaling pathway.
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